Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986256 in active systemic lupus erythematosus
2019-004021-25Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of afimetoran in systemic lupus erythematosus (SLE) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of participants who achieve an SLE Responder Index 4 response at Week 48. Started Aug 2021; status: active.
02
Drugs
afimetoran
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2019-004021-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004021-25.